KR20240021774A - Idh 돌연변이 억제제 및 이의 용도 - Google Patents
Idh 돌연변이 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20240021774A KR20240021774A KR1020237041032A KR20237041032A KR20240021774A KR 20240021774 A KR20240021774 A KR 20240021774A KR 1020237041032 A KR1020237041032 A KR 1020237041032A KR 20237041032 A KR20237041032 A KR 20237041032A KR 20240021774 A KR20240021774 A KR 20240021774A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- compounds
- pharmaceutically acceptable
- formula
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110661394.5 | 2021-06-15 | ||
| CN202110661394 | 2021-06-15 | ||
| PCT/CN2022/099018 WO2022262784A1 (zh) | 2021-06-15 | 2022-06-15 | Idh突变体抑制剂及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240021774A true KR20240021774A (ko) | 2024-02-19 |
Family
ID=84526875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237041032A Pending KR20240021774A (ko) | 2021-06-15 | 2022-06-15 | Idh 돌연변이 억제제 및 이의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240208978A1 (https=) |
| EP (1) | EP4356914A4 (https=) |
| JP (1) | JP2024524933A (https=) |
| KR (1) | KR20240021774A (https=) |
| CN (1) | CN117460512A (https=) |
| AU (1) | AU2022294860A1 (https=) |
| BR (1) | BR112023024454A2 (https=) |
| CA (1) | CA3217608A1 (https=) |
| MX (1) | MX2023013664A (https=) |
| WO (1) | WO2022262784A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026035776A1 (en) * | 2024-08-05 | 2026-02-12 | Frontier Medicines Corporation | Pi3k-alpha binding compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012184205A (ja) * | 2011-03-08 | 2012-09-27 | Dainippon Sumitomo Pharma Co Ltd | ２−アミノ置換８−オキソジヒドロプリン誘導体 |
| PL2900675T3 (pl) * | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| JP6387360B2 (ja) * | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| MA46064B1 (fr) * | 2014-09-19 | 2020-04-30 | Forma Therapeutics Inc | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
| US9624175B2 (en) * | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| ES2764523T3 (es) * | 2015-07-27 | 2020-06-03 | Lilly Co Eli | Compuestos de 7-feniletilamino-4H-pirimido[4,5-D][1,3]oxazin-2-ona y su uso como inhibidores de IDH1 mutantes |
| CN109311863B (zh) | 2016-06-06 | 2021-10-29 | 伊莱利利公司 | 突变型idh1抑制剂 |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| KR102232614B1 (ko) * | 2016-07-21 | 2021-03-29 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용 |
| ES2941631T3 (es) | 2016-12-16 | 2023-05-24 | Lilly Co Eli | Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes |
| CN110872297B (zh) * | 2018-09-04 | 2023-02-14 | 上海再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| WO2020141439A1 (en) * | 2018-12-31 | 2020-07-09 | Integral Biosciences Private Limited | Heterocyclic compounds as mutant idh inhibitors |
-
2022
- 2022-06-15 CA CA3217608A patent/CA3217608A1/en active Pending
- 2022-06-15 EP EP22824259.0A patent/EP4356914A4/en active Pending
- 2022-06-15 KR KR1020237041032A patent/KR20240021774A/ko active Pending
- 2022-06-15 BR BR112023024454A patent/BR112023024454A2/pt unknown
- 2022-06-15 US US18/287,885 patent/US20240208978A1/en active Pending
- 2022-06-15 JP JP2023577688A patent/JP2024524933A/ja active Pending
- 2022-06-15 WO PCT/CN2022/099018 patent/WO2022262784A1/zh not_active Ceased
- 2022-06-15 MX MX2023013664A patent/MX2023013664A/es unknown
- 2022-06-15 AU AU2022294860A patent/AU2022294860A1/en active Pending
- 2022-06-15 CN CN202280040684.0A patent/CN117460512A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024524933A (ja) | 2024-07-09 |
| CN117460512A (zh) | 2024-01-26 |
| WO2022262784A1 (zh) | 2022-12-22 |
| US20240208978A1 (en) | 2024-06-27 |
| AU2022294860A1 (en) | 2024-01-25 |
| CA3217608A1 (en) | 2022-12-22 |
| EP4356914A1 (en) | 2024-04-24 |
| MX2023013664A (es) | 2024-01-08 |
| BR112023024454A2 (pt) | 2024-02-06 |
| EP4356914A4 (en) | 2025-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7773987B2 (ja) | スピロ環含有キナゾリン化合物 | |
| JP7850663B2 (ja) | スピロ環含有キナゾリン化合物 | |
| CN113767103B (zh) | 新型螺环类K-Ras G12C抑制剂 | |
| EP4328224A1 (en) | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof | |
| CN115315427B (zh) | Hpk1抑制剂及其制备方法和用途 | |
| EP4365170A1 (en) | Amide compound and use thereof | |
| CN118027016A (zh) | Parg抑制剂及其制备方法和用途 | |
| EP3354647B1 (en) | Egfr kinase inhibitor and preparation method and use thereof | |
| KR20240021774A (ko) | Idh 돌연변이 억제제 및 이의 용도 | |
| RU2860311C2 (ru) | Ингибитор мутанта idh и его применение | |
| CN113880804A (zh) | 新型苯并咪唑化合物 | |
| JP7777544B2 (ja) | 新規ピラジン化合物 | |
| CN115768775B (zh) | Idh突变体抑制剂及其用途 | |
| CN119264131A (zh) | Nmt抑制剂及其制备方法和用途 | |
| CN118139846A (zh) | 一种egfr小分子抑制剂、含其的药物组合物及其用途 | |
| RU2857202C2 (ru) | Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение | |
| US12577250B2 (en) | 1,2,4-triazolone derivative as DHODH inhibitor, and preparation method therefor and use thereof | |
| EP4488263A2 (en) | Phenylurea derivative and pharmaceutical use thereof | |
| JP2025540298A (ja) | Ｈｄａｃ阻害剤およびその使用 | |
| CA3285927A1 (en) | Kif18a inhibitor | |
| JP2025534771A (ja) | Ｔｙｋ２阻害剤としての複素環式化合物及び合成及び応用 | |
| CN116249702A (zh) | 用作dhodh抑制剂的1,2,4-三唑酮衍生物 | |
| US20080299218A1 (en) | Deuterium-enriched valsartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231128 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250519 Comment text: Request for Examination of Application |